Yes he has been saying that he will lower price - I have not heard him comment on insulin which btw uses approx 2x more per dosage than subq's. Contrary to published belief, this cost was the primary reason pfizer dumped exhubra.
If you know anything about the wildly profitable, extraordinarily low margin history of the insulin market with respect to pricing, his suggestion/admission was not only new, it was colossal.
His casual mention of this was the best part to anyone listening - the way he dropped it in as if it were some small thought or development.
This issue is the singular reasons there are and have only ever been 3 pharma companies that dominate the world wide diabetes market.
This was beyond surprising - it was amazing.
yawn - when afrezza is inhaled 15 minutes before you eat it is non inferior(the mandated standard of the FDA trial) - fortunately, I can not only point to the intended difference in timing and result, I have WITNESSED first hand, that when you take Afrezza at meal(as Mann intended) rather than 15 minutes prior(by the way the FDA had to abide by this), you change the entire game... History is riddled with the path of mistimed investments...
Sentiment: Strong Buy
yes... unfortunately, I can dispute. Moreover, for someone who is as consistently and stridently invested as yourself it is a bit surprising that you would post this. If you want others to continue to take you seriously - and by others I mean the 1 percent of retail investors who together account for a bigger position than black rock(at this time) - don't be so obvious - especially when it really doesn't impact your greater point by more than 2.5 pct.
This stock has WAY TOO MANY so called longs who are not familiar with their investment.
I wish not to count you as one thus would suggest you recalculate your projections.
If you are not getting where you are off...
What is our share count again?
Umm... yeah... that has ALWAYS been the case, not to burst your bubble... There is an insurmountable degree of energy put towards a different narrative(I am not interested as to why), but if anyone actually takes the time to read contracts and maintain a VERY basic understanding of IP LAW - it is and has ALWAYS been about mnkd going this alone - and by that I mean through partnerships... their greatest risk will be there ability to defend their barriers w cash they never presently have at their dispense but obviously that does not mean they will not be unable to attain it...
I think Mr Mann saw what happened with Pfizer(non insulin player) and nektar... There are no public disruptors though some may pretend, thus Al's desire is to ensure this drug is not controlled by ANY other interests other than those ruled by a singular goal to survive, endure and eventually thrive - as financially risky as many try to paint this shadowed approach, it is where the REAL leverage resides.
actually - if you read the agreements, in particular the supply agreement, you need not hope - the "objectives" were in place - the rules of how this was to play out were not followed - case in point, read the supply agreement, then ask yourself why is Sanofi cutting the price now?
Right - one problem, if he happens to be an investor in mnkd his testimony, though objectively valid as it is captivating, would be unhelpful and easily skewed in favor of the hijacked narrative that the short side uses to their advantage.
I rarely post anymore but...
I am sure it has crossed nearly EVERYBODY'S mind who has any interest in the potential long term prosperity or failure of this novel, second to market medication.
Inhalation therapy is on its own - just that.
I am 99.99999 pct confident that children(the future) when given a choice between taking a meal time pen #$%$ or a deep breath will OVERWHELMINGLY choose the breath.
I also happen to know the data pfe obtained in their initial pediatric studies before pulling exhubra from market.
This data is quite meaningful and has NEVER once been cited from my recollection.
STRONGEST BUY EVER.
Sentiment: Strong Buy